Benzinga | May 4, 2021 04:16PM EDT

Esperion Therapeutics Q1 EPS $(3.50) Misses $(2.52) Estimate, Sales $7.98M Miss $26.12M Estimate

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(3.50) per share which missed the analyst consensus estimate of $(2.52) by 38.89 percent. This is a 23.24 percent decrease over losses of $(2.84) per share from the same period last year. The company reported quarterly sales of $7.98 million which missed the analyst consensus estimate of $26.12 million by 69.45 percent. This is a 333.70 percent increase over sales of $1.84 million the same period last year.